바이러스 벡터 및 플라스미드 DNA 제조 시장 : 벡터 유형별, 워크플로우별, 용도별, 최종 사용자별 - 세계 기회 분석 및 산업 예측(2024-2033년)

Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type (Adenovirus, Retrovirus, Adeno-Associated Virus , Lentivirus, Plasmids, Others), By Workflow By Application By End User : Global Opportunity Analysis and Industry Forecast, 2024-2033

US $ 4,425 ￦ 6,152,000

PDF (Business License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄는 5회 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 2명 이상이 이용할 경우, 추가 요금을 지불하여 라이선스 업그레이드로 최대 5명까지 이용 가능합니다.

US $ 7,412 ￦ 10,304,000

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

PDF 보고서 및 Excel 데이터를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 보고서 업데이트 서비스가 무료로 제공됩니다.

한글목차

바이러스 벡터 및 플라스미드 DNA 생산 시장

바이러스 벡터 및 플라스미드 DNA 제조 시장은 2023년 53억 달러로 평가되었고, 2024-2033년 연평균 20.4% 성장하여 2033년에는 340억 달러에 달할 것으로 예상됩니다.

바이러스 벡터 및 플라스미드 DNA는 유전공학의 중요한 구성 요소로 유전자 치료, 백신 생산 등 다양한 목적으로 활용되고 있습니다. 바이러스 벡터는 유전자 발현 또는 세포 DNA에 유전물질을 삽입하여 유전 정보를 세포에 전달하는 데 사용되는 분자 비히클의 한 형태입니다. 플라스미드 DNA는 박테리아에 존재하는 염색체 외 고리형 DNA입니다. 유전자 복제 및 유전자 치료를 위한 벡터 역할을 합니다. 바이러스 벡터 및 플라스미드 DNA의 제조는 세포 배양 시스템, 정제 과정, 박테리아 발효 등 다양한 방법으로 이루어집니다.

유전성 질환의 유병률 증가와 기술 발전으로 유전자 치료의 시행이 용이해지면서 바이러스 벡터 및 플라스미드 DNA 제조 시장의 성장을 가속하고 있습니다. 또한, 투자 급증으로 인한 연구개발 활동 증가와 정부 및 식품의약국 등 규제기관의 지원은 바이러스 벡터 및 플라스미드 DNA 제조 수요를 증가시키고 있습니다. 제조의 확장성을 높이기 위해 AI와 ML 알고리즘을 사용하는 추세가 두드러지고 있습니다. 알고리즘은 벡터 및 플라스미드의 생산을 극대화하기 위한 정확한 요구 사항과 이상적인 조건을 파악하는 데 도움이 됩니다.

그러나 작은 이물질이 전체 생산 배치를 망칠 수 있기 때문에 생산 중 오염을 방지하는 것은 어려운 과제입니다. 이러한 문제는 바이러스 벡터 및 플라스미드 DNA 생산 시장의 성장을 크게 억제합니다. 또한, 제조에 필요한 장비의 조달 및 유지보수 비용이 매우 비싸기 때문에 소규모 기업 및 연구소의 투자가 제한되어 시장 성장을 저해하고 있습니다. 또한, 세계 각국의 규제 프로세스의 차이로 인해 특정 지역에서 벡터 및 플라스미드의 유용성이 제한되고 있습니다. 예를 들어, 유럽의 가이드라인은 모든 제조 단계에서 현행 우수의약품 제조기준을 준수하도록 요구하고 있습니다. 반면, 미국 식품의약국(FDA)은 제품 개발의 첫 단계에서는 일부 재료와 모든 관련 속성 또는 허용 기준의 불명확성을 허용하고 있습니다.

부문 리뷰

바이러스 벡터 및 플라스미드 DNA 제조 시장은 벡터 유형, 워크플로우, 용도, 최종 사용자, 지역으로 구분됩니다. 벡터 유형에 따라 아데노바이러스, 레트로바이러스, 아데노부수체 바이러스(AAV), 렌치바이러스, 플라스미드, 기타로 나뉩니다. 워크플로우에 따라 업스트림 제조와 다운스트림 제조로 나뉩니다. 용도별로는 안티센스 및 RNAi 치료제, 안티센스 및 RNAi 치료제, 세포치료제, 백신치료제, 연구용으로 분류됩니다. 최종 사용자별로는 제약 및 바이오제약 기업과 연구기관으로 분류됩니다. 지역별로는 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카로 분석됩니다.

주요 조사 결과

벡터 유형별로는 아데노 동반 바이러스(AAV) 부문이 2023년 시장을 장악했습니다.

워크플로우별로는 2023년 다운스트림 제조 부문이 가장 높은 시장 점유율을 차지했습니다.

용도별로는 백신 접종 부문이 2023년 시장에서 가장 높은 점유율을 차지했습니다.

최종 사용자별로는 2023년 연구기관 부문이 높은 점유율을 차지할 것으로 예상됩니다.

지역별로는 북미가 2023년 가장 높은 수익을 올릴 것으로 예상됩니다.

이 보고서는 사용자 정의가 가능합니다.

• 규제 가이드라인
• 고객의 관심사에 따른 기업 프로파일 추가
• 국가별 또는 지역별 추가 분석 - 시장 규모 및 전망
• 기업 프로파일 확대 목록
• 과거 시장 데이터
• 주요 진입기업 세부 정보(위치, 연락처, 공급업체/벤더 네트워크 등 포함, 엑셀 형식)

목차

제1장 서론

제2장 주요 요약

제3장 시장 구도

• 시장 정의와 범위
• 주요 조사 결과
  • 주요 투자 기회
  • 주요 성공 전략
• Porter의 Five Forces 분석
• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회

제4장 바이러스 벡터 및 플라스미드 DNA 제조 시장 : 벡터 유형별

• 시장 개요
• 아데노바이러스
• 레트로바이러스
• 아데노 관련 바이러스(AAV)
• 렌티바이러스
• 플라스미드
• 기타

제5장 바이러스 벡터 및 플라스미드 DNA 제조 시장 : 워크플로우별

• 시장 개요
• Upstream 제조
• Downstream 제조

제6장 바이러스 벡터 및 플라스미드 DNA 제조 시장 : 용도별

• 시장 개요
• 안티센스 RNAi 요법
• 안티센스 RNAi 요법
• 세포치료
• 백신요법
• 연구 용도

제7장 바이러스 벡터 및 플라스미드 DNA 제조 시장 : 최종사용자별

• 시장 개요
• 제약 바이오의약품 기업
• 연구기관

제8장 바이러스 벡터 및 플라스미드 DNA 제조 시장 : 지역별

• 시장 개요
• 북미
  • 주요 시장 동향과 기회
  • 미국 바이러스 벡터 및 플라스미드 DNA 제조 시장
  • 캐나다 바이러스 벡터 및 플라스미드 DNA 제조 시장
  • 멕시코 바이러스 벡터 및 플라스미드 DNA 제조 시장
• 유럽
  • 주요 시장 동향과 기회
  • 독일 바이러스 벡터 및 플라스미드 DNA 제조 시장
  • 프랑스 바이러스 벡터 및 플라스미드 DNA 제조 시장
  • 영국 바이러스 벡터 및 플라스미드 DNA 제조 시장
  • 이탈리아 바이러스 벡터 및 플라스미드 DNA 제조 시장
  • 스페인 바이러스 벡터 및 플라스미드 DNA 제조 시장
  • 기타 유럽 바이러스 벡터 및 플라스미드 DNA 제조 시장
• 아시아태평양
  • 주요 시장 동향과 기회
  • 일본 바이러스 벡터 및 플라스미드 DNA 제조 시장
  • 중국 바이러스 벡터 및 플라스미드 DNA 제조 시장
  • 호주 바이러스 벡터 및 플라스미드 DNA 제조 시장
  • 인도 바이러스 벡터 및 플라스미드 DNA 제조 시장
  • 한국 바이러스 벡터 및 플라스미드 DNA 제조 시장
  • 기타 아시아태평양 바이러스 벡터 및 플라스미드 DNA 제조 시장
• 라틴아메리카/중동 및 아프리카
  • 주요 시장 동향과 기회
  • 브라질 바이러스 벡터 및 플라스미드 DNA 제조 시장
  • 사우디아라비아 바이러스 벡터 및 플라스미드 DNA 제조 시장
  • 남아프리카공화국 바이러스 벡터 및 플라스미드 DNA 제조 시장
  • 기타 라틴아메리카/중동 및 아프리카 바이러스 벡터 및 플라스미드 DNA 제조 시장

제9장 경쟁 구도

• 서론
• 주요 성공 전략
• 주요 10개 기업의 제품 매핑
• 경쟁 대시보드
• 경쟁 히트맵
• 주요 기업의 포지셔닝(2023년)

제10장 기업 개요

• Merck KGaA
• Lonza Group AG
• FUJIFILM Corporation
• Thermo Fisher Scientific
• Cobra Biologics
• Catalent Inc.
• WuXi Biologics.
• TakarBio Inc
• Waisman Biomanufacturing, LLC
• Genezen Laboratories

LSH

영문 목차

영문목차

Viral Vectors and Plasmid DNA Manufacturing Market

The viral vectors and plasmid DNA manufacturing market was valued at $5.3 billion in 2023 and is projected to reach $34.0 billion by 2033, growing at a CAGR of 20.4% from 2024 to 2033.

Viral vector and plasmid DNA are the crucial components of genetic engineering, utilized for diverse purposes such as gene therapy and vaccine production. A viral vector is a form of molecular vehicle used to transfer genetic information to the cells either through gene expression or integration of genetic material into the cell's DNA. Plasmid DNA is an extrachromosomal circular piece of DNA present in bacteria. It serves as a vector for gene cloning, and gene therapy. The manufacturing of viral vectors and plasmid DNA is accomplished through various methods such as cell culture systems, purification processes, or bacterial fermentation.

Increase in the prevalence of genetic disorders and advancements in technology have facilitated the execution of gene therapies, thereby driving the growth of the viral vectors and plasmid DNA manufacturing market. In addition, rise in R&D activities due to surge in investments & support from government and regulatory agencies such as the Food and Drug administration is boosting the demand for the manufacturing for viral vectors and plasmid DNA. To enhance the scalability of production, the trend of using AI and ML algorithms is gaining prominence. The algorithm helps in identifying the precise requirements and ideal conditions to maximize the production of vectors and plasmid.

However, preventing contamination during manufacturing is challenging as a tiny foreign particle is capable of spoiling the entire production batch. This challenge significantly restrains the growth of the viral vectors and plasmid DNA manufacturing market. In addition, the procurement and maintenance of the equipment required for production is highly expensive, which limits several small-scale firms and laboratories from investing, hence hampering the market growth. Moreover, discrepancies in the regulatory process across the globe restrict the utility of the vectors and plasmid in certain regions. For instance, the European guidelines have mandated the compliance of products with the current good manufacturing practices standards at all stages of production. Contrarily, as per the U.S. Food and Drug Administration, it is acceptable that some materials and all relevant attributes or acceptance criteria remain unknown at stage 1 of product development.

Segment Review

The viral vectors and plasmid DNA manufacturing market is segmented into vector type, workflow, application, end user, and region. On the basis of vector type, the market is divided into adenovirus, retrovirus, adeno-associated virus (AAV), lentivirus, plasmids, and others. Depending on workflow, it is bifurcated into upstream manufacturing and downstream manufacturing. As per application, it is classified into antisense & RNAi therapy, antisense & RNAi therapy, cell therapy, vaccinology, and research applications. According to end user, it is categorized into pharmaceutical & biopharmaceutical companies and research institutes. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of vector type, the adeno-associated virus (AAV) segment dominated the market in 2023.

Depending on workflow, the downstream manufacturing segment accounted for a high market share in 2023.

As per application, the vaccinology segment acquired a high stake in the market in 2023.

According to end user, the research institutes segment was the highest shareholder in 2023.

Region wise, North America was the highest revenue generator in 2023.

Competition Analysis

The leading players operating in the global viral vectors and plasmid DNA manufacturing market include Merck KGaA, Lonza Group AG, FUJIFILM Corporation, thermo fisher scientific, Cobra Biologics, Catalent Inc., WuXi Biologics., TakarBio Inc, Waisman Biomanufacturing, LLC, and Genezen laboratories. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships, to strengthen their foothold in the competitive market.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

• Regulatory Guidelines
• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast
• Expanded list for Company Profiles
• Historic market data
• Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Vector Type

• Adenovirus
• Retrovirus
• Adeno-Associated Virus (AAV)
• Lentivirus
• Plasmids
• Others

By Workflow

• Upstream Manufacturing
• Downstream Manufacturing

By Application

• Antisense RNAi Therapy
• Antisense RNAi Therapy
• Cell Therapy
• Vaccinology
• Research Applications

By End User

• Pharmaceutical Biopharmaceutical Companies
• Research Institutes

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players:

• Merck KGaA
• Lonza Group AG
• FUJIFILM Corporation
• Thermo Fisher Scientific Inc.
• Cobra Biologics
• Catalent Inc.
• WuXi Biologics.
• TakarBio Inc
• Waisman Biomanufacturing, LLC
• Genezen laboratories

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report Description
• 1.2. Key Market Segments
• 1.3. Key Benefits
• 1.4. Research Methodology
  • 1.4.1. Primary Research
  • 1.4.2. Secondary Research
  • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

• 3.1. Market Definition and Scope
• 3.2. Key Findings
  • 3.2.1. Top Investment Pockets
  • 3.2.2. Top Winning Strategies
• 3.3. Porter's Five Forces Analysis
  • 3.3.1. Bargaining Power of Suppliers
  • 3.3.2. Threat of New Entrants
  • 3.3.3. Threat of Substitutes
  • 3.3.4. Competitive Rivalry
  • 3.3.5. Bargaining Power among Buyers
• 3.4. Market Dynamics
  • 3.4.1. Drivers
  • 3.4.2. Restraints
  • 3.4.3. Opportunities

CHAPTER 4: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE

• 4.1. Market Overview
  • 4.1.1 Market Size and Forecast, By Vector Type
• 4.2. Adenovirus
  • 4.2.1. Key Market Trends, Growth Factors and Opportunities
  • 4.2.2. Market Size and Forecast, By Region
  • 4.2.3. Market Share Analysis, By Country
• 4.3. Retrovirus
  • 4.3.1. Key Market Trends, Growth Factors and Opportunities
  • 4.3.2. Market Size and Forecast, By Region
  • 4.3.3. Market Share Analysis, By Country
• 4.4. Adeno-Associated Virus (AAV)
  • 4.4.1. Key Market Trends, Growth Factors and Opportunities
  • 4.4.2. Market Size and Forecast, By Region
  • 4.4.3. Market Share Analysis, By Country
• 4.5. Lentivirus
  • 4.5.1. Key Market Trends, Growth Factors and Opportunities
  • 4.5.2. Market Size and Forecast, By Region
  • 4.5.3. Market Share Analysis, By Country
• 4.6. Plasmids
  • 4.6.1. Key Market Trends, Growth Factors and Opportunities
  • 4.6.2. Market Size and Forecast, By Region
  • 4.6.3. Market Share Analysis, By Country
• 4.7. Others
  • 4.7.1. Key Market Trends, Growth Factors and Opportunities
  • 4.7.2. Market Size and Forecast, By Region
  • 4.7.3. Market Share Analysis, By Country

CHAPTER 5: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW

• 5.1. Market Overview
  • 5.1.1 Market Size and Forecast, By Workflow
• 5.2. Upstream Manufacturing
  • 5.2.1. Key Market Trends, Growth Factors and Opportunities
  • 5.2.2. Market Size and Forecast, By Region
  • 5.2.3. Market Share Analysis, By Country
• 5.3. Downstream Manufacturing
  • 5.3.1. Key Market Trends, Growth Factors and Opportunities
  • 5.3.2. Market Size and Forecast, By Region
  • 5.3.3. Market Share Analysis, By Country

CHAPTER 6: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION

• 6.1. Market Overview
  • 6.1.1 Market Size and Forecast, By Application
• 6.2. Antisense RNAi Therapy
  • 6.2.1. Key Market Trends, Growth Factors and Opportunities
  • 6.2.2. Market Size and Forecast, By Region
  • 6.2.3. Market Share Analysis, By Country
• 6.3. Antisense RNAi Therapy
  • 6.3.1. Key Market Trends, Growth Factors and Opportunities
  • 6.3.2. Market Size and Forecast, By Region
  • 6.3.3. Market Share Analysis, By Country
• 6.4. Cell Therapy
  • 6.4.1. Key Market Trends, Growth Factors and Opportunities
  • 6.4.2. Market Size and Forecast, By Region
  • 6.4.3. Market Share Analysis, By Country
• 6.5. Vaccinology
  • 6.5.1. Key Market Trends, Growth Factors and Opportunities
  • 6.5.2. Market Size and Forecast, By Region
  • 6.5.3. Market Share Analysis, By Country
• 6.6. Research Applications
  • 6.6.1. Key Market Trends, Growth Factors and Opportunities
  • 6.6.2. Market Size and Forecast, By Region
  • 6.6.3. Market Share Analysis, By Country

CHAPTER 7: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER

• 7.1. Market Overview
  • 7.1.1 Market Size and Forecast, By End User
• 7.2. Pharmaceutical Biopharmaceutical Companies
  • 7.2.1. Key Market Trends, Growth Factors and Opportunities
  • 7.2.2. Market Size and Forecast, By Region
  • 7.2.3. Market Share Analysis, By Country
• 7.3. Research Institutes
  • 7.3.1. Key Market Trends, Growth Factors and Opportunities
  • 7.3.2. Market Size and Forecast, By Region
  • 7.3.3. Market Share Analysis, By Country

CHAPTER 8: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY REGION

• 8.1. Market Overview
  • 8.1.1 Market Size and Forecast, By Region
• 8.2. North America
  • 8.2.1. Key Market Trends and Opportunities
  • 8.2.2. Market Size and Forecast, By Vector Type
  • 8.2.3. Market Size and Forecast, By Workflow
  • 8.2.4. Market Size and Forecast, By Application
  • 8.2.5. Market Size and Forecast, By End User
  • 8.2.6. Market Size and Forecast, By Country
  • 8.2.7. U.S. Viral Vectors and Plasmid DNA Manufacturing Market
    • 8.2.7.1. Market Size and Forecast, By Vector Type
    • 8.2.7.2. Market Size and Forecast, By Workflow
    • 8.2.7.3. Market Size and Forecast, By Application
    • 8.2.7.4. Market Size and Forecast, By End User
  • 8.2.8. Canada Viral Vectors and Plasmid DNA Manufacturing Market
    • 8.2.8.1. Market Size and Forecast, By Vector Type
    • 8.2.8.2. Market Size and Forecast, By Workflow
    • 8.2.8.3. Market Size and Forecast, By Application
    • 8.2.8.4. Market Size and Forecast, By End User
  • 8.2.9. Mexico Viral Vectors and Plasmid DNA Manufacturing Market
    • 8.2.9.1. Market Size and Forecast, By Vector Type
    • 8.2.9.2. Market Size and Forecast, By Workflow
    • 8.2.9.3. Market Size and Forecast, By Application
    • 8.2.9.4. Market Size and Forecast, By End User
• 8.3. Europe
  • 8.3.1. Key Market Trends and Opportunities
  • 8.3.2. Market Size and Forecast, By Vector Type
  • 8.3.3. Market Size and Forecast, By Workflow
  • 8.3.4. Market Size and Forecast, By Application
  • 8.3.5. Market Size and Forecast, By End User
  • 8.3.6. Market Size and Forecast, By Country
  • 8.3.7. Germany Viral Vectors and Plasmid DNA Manufacturing Market
    • 8.3.7.1. Market Size and Forecast, By Vector Type
    • 8.3.7.2. Market Size and Forecast, By Workflow
    • 8.3.7.3. Market Size and Forecast, By Application
    • 8.3.7.4. Market Size and Forecast, By End User
  • 8.3.8. France Viral Vectors and Plasmid DNA Manufacturing Market
    • 8.3.8.1. Market Size and Forecast, By Vector Type
    • 8.3.8.2. Market Size and Forecast, By Workflow
    • 8.3.8.3. Market Size and Forecast, By Application
    • 8.3.8.4. Market Size and Forecast, By End User
  • 8.3.9. UK Viral Vectors and Plasmid DNA Manufacturing Market
    • 8.3.9.1. Market Size and Forecast, By Vector Type
    • 8.3.9.2. Market Size and Forecast, By Workflow
    • 8.3.9.3. Market Size and Forecast, By Application
    • 8.3.9.4. Market Size and Forecast, By End User
  • 8.3.10. Italy Viral Vectors and Plasmid DNA Manufacturing Market
    • 8.3.10.1. Market Size and Forecast, By Vector Type
    • 8.3.10.2. Market Size and Forecast, By Workflow
    • 8.3.10.3. Market Size and Forecast, By Application
    • 8.3.10.4. Market Size and Forecast, By End User
  • 8.3.11. Spain Viral Vectors and Plasmid DNA Manufacturing Market
    • 8.3.11.1. Market Size and Forecast, By Vector Type
    • 8.3.11.2. Market Size and Forecast, By Workflow
    • 8.3.11.3. Market Size and Forecast, By Application
    • 8.3.11.4. Market Size and Forecast, By End User
  • 8.3.12. Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market
    • 8.3.12.1. Market Size and Forecast, By Vector Type
    • 8.3.12.2. Market Size and Forecast, By Workflow
    • 8.3.12.3. Market Size and Forecast, By Application
    • 8.3.12.4. Market Size and Forecast, By End User
• 8.4. Asia-Pacific
  • 8.4.1. Key Market Trends and Opportunities
  • 8.4.2. Market Size and Forecast, By Vector Type
  • 8.4.3. Market Size and Forecast, By Workflow
  • 8.4.4. Market Size and Forecast, By Application
  • 8.4.5. Market Size and Forecast, By End User
  • 8.4.6. Market Size and Forecast, By Country
  • 8.4.7. Japan Viral Vectors and Plasmid DNA Manufacturing Market
    • 8.4.7.1. Market Size and Forecast, By Vector Type
    • 8.4.7.2. Market Size and Forecast, By Workflow
    • 8.4.7.3. Market Size and Forecast, By Application
    • 8.4.7.4. Market Size and Forecast, By End User
  • 8.4.8. China Viral Vectors and Plasmid DNA Manufacturing Market
    • 8.4.8.1. Market Size and Forecast, By Vector Type
    • 8.4.8.2. Market Size and Forecast, By Workflow
    • 8.4.8.3. Market Size and Forecast, By Application
    • 8.4.8.4. Market Size and Forecast, By End User
  • 8.4.9. Australia Viral Vectors and Plasmid DNA Manufacturing Market
    • 8.4.9.1. Market Size and Forecast, By Vector Type
    • 8.4.9.2. Market Size and Forecast, By Workflow
    • 8.4.9.3. Market Size and Forecast, By Application
    • 8.4.9.4. Market Size and Forecast, By End User
  • 8.4.10. India Viral Vectors and Plasmid DNA Manufacturing Market
    • 8.4.10.1. Market Size and Forecast, By Vector Type
    • 8.4.10.2. Market Size and Forecast, By Workflow
    • 8.4.10.3. Market Size and Forecast, By Application
    • 8.4.10.4. Market Size and Forecast, By End User
  • 8.4.11. South Korea Viral Vectors and Plasmid DNA Manufacturing Market
    • 8.4.11.1. Market Size and Forecast, By Vector Type
    • 8.4.11.2. Market Size and Forecast, By Workflow
    • 8.4.11.3. Market Size and Forecast, By Application
    • 8.4.11.4. Market Size and Forecast, By End User
  • 8.4.12. Rest of Asia-Pacific Viral Vectors and Plasmid DNA Manufacturing Market
    • 8.4.12.1. Market Size and Forecast, By Vector Type
    • 8.4.12.2. Market Size and Forecast, By Workflow
    • 8.4.12.3. Market Size and Forecast, By Application
    • 8.4.12.4. Market Size and Forecast, By End User
• 8.5. LAMEA
  • 8.5.1. Key Market Trends and Opportunities
  • 8.5.2. Market Size and Forecast, By Vector Type
  • 8.5.3. Market Size and Forecast, By Workflow
  • 8.5.4. Market Size and Forecast, By Application
  • 8.5.5. Market Size and Forecast, By End User
  • 8.5.6. Market Size and Forecast, By Country
  • 8.5.7. Brazil Viral Vectors and Plasmid DNA Manufacturing Market
    • 8.5.7.1. Market Size and Forecast, By Vector Type
    • 8.5.7.2. Market Size and Forecast, By Workflow
    • 8.5.7.3. Market Size and Forecast, By Application
    • 8.5.7.4. Market Size and Forecast, By End User
  • 8.5.8. Saudi Arabia Viral Vectors and Plasmid DNA Manufacturing Market
    • 8.5.8.1. Market Size and Forecast, By Vector Type
    • 8.5.8.2. Market Size and Forecast, By Workflow
    • 8.5.8.3. Market Size and Forecast, By Application
    • 8.5.8.4. Market Size and Forecast, By End User
  • 8.5.9. South Africa Viral Vectors and Plasmid DNA Manufacturing Market
    • 8.5.9.1. Market Size and Forecast, By Vector Type
    • 8.5.9.2. Market Size and Forecast, By Workflow
    • 8.5.9.3. Market Size and Forecast, By Application
    • 8.5.9.4. Market Size and Forecast, By End User
  • 8.5.10. Rest of LAMEA Viral Vectors and Plasmid DNA Manufacturing Market
    • 8.5.10.1. Market Size and Forecast, By Vector Type
    • 8.5.10.2. Market Size and Forecast, By Workflow
    • 8.5.10.3. Market Size and Forecast, By Application
    • 8.5.10.4. Market Size and Forecast, By End User

CHAPTER 9: COMPETITIVE LANDSCAPE

• 9.1. Introduction
• 9.2. Top Winning Strategies
• 9.3. Product Mapping of Top 10 Player
• 9.4. Competitive Dashboard
• 9.5. Competitive Heatmap
• 9.6. Top Player Positioning, 2023

CHAPTER 10: COMPANY PROFILES

• 10.1. Merck KGaA
  • 10.1.1. Company Overview
  • 10.1.2. Key Executives
  • 10.1.3. Company Snapshot
  • 10.1.4. Operating Business Segments
  • 10.1.5. Product Portfolio
  • 10.1.6. Business Performance
  • 10.1.7. Key Strategic Moves and Developments
• 10.2. Lonza Group AG
  • 10.2.1. Company Overview
  • 10.2.2. Key Executives
  • 10.2.3. Company Snapshot
  • 10.2.4. Operating Business Segments
  • 10.2.5. Product Portfolio
  • 10.2.6. Business Performance
  • 10.2.7. Key Strategic Moves and Developments
• 10.3. FUJIFILM Corporation
  • 10.3.1. Company Overview
  • 10.3.2. Key Executives
  • 10.3.3. Company Snapshot
  • 10.3.4. Operating Business Segments
  • 10.3.5. Product Portfolio
  • 10.3.6. Business Performance
  • 10.3.7. Key Strategic Moves and Developments
• 10.4. Thermo Fisher Scientific
  • 10.4.1. Company Overview
  • 10.4.2. Key Executives
  • 10.4.3. Company Snapshot
  • 10.4.4. Operating Business Segments
  • 10.4.5. Product Portfolio
  • 10.4.6. Business Performance
  • 10.4.7. Key Strategic Moves and Developments
• 10.5. Cobra Biologics
  • 10.5.1. Company Overview
  • 10.5.2. Key Executives
  • 10.5.3. Company Snapshot
  • 10.5.4. Operating Business Segments
  • 10.5.5. Product Portfolio
  • 10.5.6. Business Performance
  • 10.5.7. Key Strategic Moves and Developments
• 10.6. Catalent Inc.
  • 10.6.1. Company Overview
  • 10.6.2. Key Executives
  • 10.6.3. Company Snapshot
  • 10.6.4. Operating Business Segments
  • 10.6.5. Product Portfolio
  • 10.6.6. Business Performance
  • 10.6.7. Key Strategic Moves and Developments
• 10.7. WuXi Biologics.
  • 10.7.1. Company Overview
  • 10.7.2. Key Executives
  • 10.7.3. Company Snapshot
  • 10.7.4. Operating Business Segments
  • 10.7.5. Product Portfolio
  • 10.7.6. Business Performance
  • 10.7.7. Key Strategic Moves and Developments
• 10.8. TakarBio Inc
  • 10.8.1. Company Overview
  • 10.8.2. Key Executives
  • 10.8.3. Company Snapshot
  • 10.8.4. Operating Business Segments
  • 10.8.5. Product Portfolio
  • 10.8.6. Business Performance
  • 10.8.7. Key Strategic Moves and Developments
• 10.9. Waisman Biomanufacturing, LLC
  • 10.9.1. Company Overview
  • 10.9.2. Key Executives
  • 10.9.3. Company Snapshot
  • 10.9.4. Operating Business Segments
  • 10.9.5. Product Portfolio
  • 10.9.6. Business Performance
  • 10.9.7. Key Strategic Moves and Developments
• 10.10. Genezen Laboratories
  • 10.10.1. Company Overview
  • 10.10.2. Key Executives
  • 10.10.3. Company Snapshot
  • 10.10.4. Operating Business Segments
  • 10.10.5. Product Portfolio
  • 10.10.6. Business Performance
  • 10.10.7. Key Strategic Moves and Developments

관련자료